Agendia to Present Five Posters Demonstrating the Expanding Clinical Utility of MammaPrint + BluePrint at the 2025 San Antonio Breast Cancer Symposium
Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new results from the ongoing real-world FLEX Study (NCT03053193) at the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place December 9-12 in San Antonio, Texas.
The company will present five posters, led by Agendia investigators and independent academic collaborators, that collectively highlight the broad clinical impact of MammaPrint® + BluePrint® genomic profiling in optimizing treatment decisions and improving outcomes for patients with hormone receptor positive, HER2-negative (HR+/HER2–) early breast cancer (EBC).
“We look forward to sharing these new findings from the FLEX Study, which spans more than 20,000 participants across 100 global sites, making it the largest and most diverse real-world evidence cohort for early-stage breast cancer,” said William Audeh, M.D., Chief Medical Officer at Agendia. “These results underscore our commitment to generating robust clinical evidence in settings beyond traditional clinical trials, ensuring the results can inform personalized treatment decisions across diverse patient populations and everyday clinical practice.”
The full list of abstracts & poster presentations is as follows:
3.2yr Updated Outcome Analysis of ACT-T Benefit by MammaPrint Risk Result
Improved 3-year IDFS with anthracycline-based therapy for patients with 70-gene signature High 2, Luminal B, HR+HER2– EBC
Poster #PS2-07-03 | Dec. 10, 5:00 PM - 6:30 PM | Presenter: Joyce O'Shaughnessy
MammaPrint Provides Stronger Prognostic Value Than Histologic Grade
70-gene signature high risk classification provides stronger prognostic value than histologic grade in HR+HER2– EBC
Poster #PS5-04-19 | Dec. 12, 12:30-2:00 PM | Presenter: Erin Cobain
Older Patients with Aggressive Breast Cancer May Benefit from Chemotherapy
HR+HER2– Patients Aged ≥70 with High Risk MammaPrint Benefit from Chemotherapy
Poster #PS3-08-17 | Dec. 11, 12.30 PM - 2 PM | Presenter: Reshma Mahtani
Understanding Breast Cancer in Overweight Latin American Patients
Distinct Immune and Metabolic Profiles in Latin American Breast Cancer Patients with Obesity
Poster #PS4-09-09 | Dec. 11, 5:00 PM - 6:30 PM | Presenter: Marcela Mazo Canola
30,000-Patient Study Expanding to Improve Breast Cancer Outcomes
FLEX: From Genomic Profiling to Real-World Insights in 30,000 Patients with Early-Stage Breast Cancer
Poster #PS5-09-19 | Dec. 12 12:30-2:00 PM | Presenter: Linsey P. Gold
About Agendia
Agendia is a global leader in precision oncology focused on early-stage breast cancer. The company’s genomic assays, MammaPrint + BluePrint, deliver essential biological insights to inform personalized treatment decisions for patients and their care teams. With operations in Amsterdam and Irvine, Agendia partners with academic and community oncology centers worldwide to generate real-world evidence through the landmark FLEX Study (NCT03053193), the largest whole-transcriptome registry of early-stage breast cancer.
About MammaPrint
MammaPrint is a clinically validated genomic test that analyzes the expression of 70 genes in breast cancer tissue to determine the likelihood of distant metastasis. By providing risk stratification into four categories — UltraLow Risk, Low Risk, High Risk 1, and High Risk 2 — MammaPrint enables more personalized, data-driven guidance to chemotherapy and endocrine therapy planning.
About BluePrint
BluePrint is a 80-gene molecular subtyping assay that reveals the underlying biology driving tumor growth, classifying tumors as Luminal-type, HER2-type, or Basal-type. By defining intrinsic subtypes beyond conventional pathology, BluePrint offers deeper biological understanding to refine therapeutic decision-making and enhance clinical outcomes.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251104247663/en/
Contacts
Media contact
marketing@agendia.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BitGo yn Sicrhau Cymeradwyaeth OCC i Drosi i Fanc Ymddiriedolaeth Genedlaethol Siartredig Ffederal13.12.2025 02:13:00 CET | Pressmeddelande
Cyhoeddodd BitGo Holdings, Inc. (“BitGo”), y cwmni seilwaith asedau digidol, heddiw fod Swyddfa Rheolwr yr Arian Cyfred (“OCC”) wedi cymeradwyo ei gais i drosi BitGo Trust Company, Inc., cwmni ymddiriedolaeth siartredig De Dakota, i fanc cenedlaethol o'r enw BitGo Bank & Trust, National Association (N.A.). Gyda chymeradwyaeth OCC heddiw o'i drosi, mae is-gwmni Cwmni Ymddiriedolaeth BitGo bellach yn gweithredu fel BitGo Bank & Trust, National Association (N.A.). Bydd BitGo Bank & Trust, N.A. yn gweithredu o dan un gyfundrefn oruchwylio ffederal unffurf, gan ei alluogi i ddarparu'r eglurder, y llywodraethiant, a'r sicrwydd rheoleiddiol y mae sefydliadau'n eu disgwyl gan ymddiriedolwr a reoleiddir yn ffederal. Mae'r gymeradwyaeth hon yn atgyfnerthu safle BitGo fel sylfaen sefydliadol ar gyfer y system ariannol fodern, gan gyfuno goruchwyliaeth ar lefel banc â'r diogelwch, y cydymffurfiaeth, a'r graddadwyedd sy'n diffinio seilwaith BitGo. O dan siarter y banc cenedlaethol, ac yn amodol ar
FIA, Formula 1 Group and All 11 Race Teams Officially Sign the Ninth Concorde Agreement, Securing Strength and Stability for the Sport in Pivotal Five-Year Agreement12.12.2025 17:10:00 CET | Press Release
The Fédération Internationale de l'Automobile (FIA), the global governing body for motor sport and the federation for mobility organisations worldwide, and Formula 1 Group, the Commercial Rights Holder, have today announced the signing of the Concorde Governance Agreement, a crucial contract defining the regulatory framework and governance terms of the FIA Formula One World Championship until 2030. This follows the announcement in March that the 2026 Commercial Concorde Agreement had been signed by all the teams and Formula 1 Group. Together, these agreements constitute the ninth Concorde Agreement, representing a major step forward in the professionalisation and global development of the sport. First introduced in 1981, the Concorde Agreements are designed to promote sporting fairness, technological innovation and operational excellence, and align all key stakeholders around a shared vision for structured governance and continued growth of the sport. Each iteration of the Concorde Agr
Anabranch Capital Management, LP supports relisting of SmartCraft ASA to Nasdaq Stockholm12.12.2025 16:26:00 CET | Press Release
Reference is made to the stock exchange announcement by SmartCraft ASA ("SmartCraft" or the "Company") on 1 December 2025 regarding the contemplated relisting of SmartCraft from Euronext Oslo Børs to Nasdaq Stockholm (the "Relisting") and the announcement of a cross-border merger to effect the Relisting. Funds managed by Anabranch Capital Management, LP (“Anabranch”) intend to vote in favour of the merger plan resolved by the boards of SmartCraft and its Swedish wholly owned subsidiary, SmartCraft Group AB (publ), to effect the Relisting at the Company's extraordinary general meeting planned for January 2025 (the "EGM"). Anabranch intends to vote with all Anabranch shares held at the Record Date for the EGM in favour of the relisting effected by the merger plan. Funds managed by Anabranch currently hold approximately 15.9 million shares in SmartCraft. Disclaimer: The views expressed are those of the authors and Anabranch Capital Management, LP as of the date referenced and are subject
Mohammed Ben Sulayem Re-Elected as President of the FIA12.12.2025 15:49:00 CET | Press Release
The Fédération Internationale de l’Automobile (FIA), the global governing body for motor sport and the federation for mobility organisations worldwide, today confirms that Mohammed Ben Sulayem has been re-elected as President of the FIA, following the election of his Presidential List by the General Assembly in Tashkent, Republic of Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251212213181/en/ President Mohammed Ben Sulayem now begins his second four-year term, having overseen a period of significant renewal and stabilisation for the organisation since his initial election in 2021. Over the past four years, the FIA has undergone a wide-ranging transformation, improving governance, operations and restoring the financial health of the federation. These changes have strengthened the FIA’s position as the world’s governing body for motorsport and the leading authority on safe, sustainable, and affordable mobility.
Capcom’s All-new IP PRAGMATA to Launch on April 24, 2026!12.12.2025 15:00:00 CET | Press Release
Capcom Co., Ltd. (TOKYO:9697) today announced that sci-fi action-adventure game PRAGMATA, a completely new IP, is scheduled for release on April 24, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251212791950/en/ PRAGMATA Key Art PRAGMATA is a new type of sci-fi action-adventure game mixing puzzle and action elements. In the game, which takes place on the moon in a near-future world, the spacesuit-clad Hugh and android girl Diana cooperate while fighting their way back to Earth. By bringing the title to Nintendo Switch™ 2 in addition to PlayStation®5 system, Xbox Series X|S and PC, Capcom looks to further advance its multi-platform strategy and expand its user base. Moreover, a playable demo of the game will be released first on PC starting today, December 12, to further convey the appeal of the title. The company hopes that players look forward to PRAGMATA, which has already garnered acclaim for its playable demos at
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom